Mather Group’s West Pharmaceutical WST Stock Holding History

Mather Group’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$318K	Sell	885 -22	-2%	-$6.73K	﹤0.01%	656
2026 Q1	$227K	Buy	+907	New	+$226K	﹤0.01%	700
2025 Q4	–	Sell	-686	Closed	-$180K	–	1658
2025 Q3	$180K	Buy	+686	New	+$167K	﹤0.01%	652
2025 Q2	–	Sell	-884	Closed	-$198K	–	1731
2025 Q1	$198K	Sell	884 -225	-20%	-$62K	﹤0.01%	591
2024 Q4	$363K	Sell	1,109 -357	-24%	-$112K	﹤0.01%	425
2024 Q3	$440K	Buy	1,466 +143	+11%	+$43.8K	0.01%	394
2024 Q2	$524K	Buy	1,323 +142	+12%	+$50.2K	0.01%	406
2024 Q1	$416K	Hold	1,181	–	–	0.01%	377
2023 Q4	$416K	Sell	1,181 -54	-4%	-$19.1K	0.01%	388
2023 Q3	$463K	Buy	1,235 +46	+4%	+$17.8K	0.01%	339
2023 Q2	$455K	Buy	1,189 +297	+33%	+$106K	0.01%	366
2023 Q1	$309K	Buy	+892	New	+$261K	0.01%	389
2022 Q4	–	Sell	-1,011	Closed	-$249K	–	513
2022 Q3	$249K	Sell	1,011 -12	-1%	-$3.66K	0.01%	410
2022 Q2	$309K	Buy	+1,023	New	+$333K	0.01%	303

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Mather Group's WST Position: Q2 2026 in Review

Mather Group reduced its West Pharmaceutical (WST) stake by 2.4% in Q2 2026, selling an estimated $6.73K and leaving 885 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #656.

Mather Group first reported a position in WST in Q2 2022 and has held it in 14 quarters since. The position peaked at $524K in Q2 2024. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Mather Group held 885 shares of West Pharmaceutical worth $318K as of Q2 2026.
Mather Group sold 22 West Pharmaceutical shares in Q2 2026, an estimated $6.73K.
West Pharmaceutical made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #656 holding.
Mather Group first reported a position in West Pharmaceutical in Q2 2022 and has held it in 14 quarters since.
Mather Group's West Pharmaceutical position peaked at $524K in Q2 2024.
831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.